#1 Clinical Trials Search in Europe

HSP-CAR19M

Clinical trials are studying HSP-CAR19M in adults with certain B-cell non-Hodgkin lymphomas. These studies aim to assess safety, toxicity, and possible benefit of the treatment. The main target groups are people with relapsed or refractory large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

Table of contents

Trial overview

The available trial is an interventional study, which means people receive a treatment that is being tested.[1] It is studying HSP-CAR19M in adults with B-cell non-Hodgkin lymphoma.[1]

The study is authorised and plans to enroll 40 participants.[1]

Who the study is for

The trial is for adults with relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma.[1] Relapsed means the cancer came back after treatment, and refractory means it did not respond well to treatment.[1]

These conditions are all types of B-cell non-Hodgkin lymphoma, which are cancers that start in B cells, a kind of white blood cell.[1]

Study phase and design

This is a Phase 1/2 trial.[1] Phase 1/2 studies first look closely at safety, then also look for early signs that the treatment may help.[1]

The brief summary says the study is evaluating the safety, toxicity, and efficacy of autologous memory T cells that are expanded outside the body and genetically modified with a chimeric antigen receptor targeting CD19.[1] In simple terms, the trial is testing a personalized cell therapy made from the patient’s own cells.[1]

What the trial measures

The primary outcome is safety associated with infusion of HSP-CAR19M cells.[1] Safety outcomes help researchers see whether the treatment can be given without causing unacceptable problems.[1]

In the expansion phase, the study also evaluates safety and efficacy of HSP-CAR19M cell administration.[1] Efficacy means how well the treatment works against the cancer.[1]

Treatments used in the study

The intervention list includes HSP-CAR19M and several other drugs given by intravenous infusion.[1] The trial data do not explain the full role of each listed drug, so the key point is that HSP-CAR19M is part of a treatment plan studied in this trial.[1]

Intravenous infusion means a treatment is given through a vein, usually over time.[1]

What the trial details mean for patients

For patients, this study is an early-stage attempt to learn whether HSP-CAR19M can be used safely in hard-to-treat B-cell lymphomas.[1] The trial is not just looking at one disease, but at several related lymphoma types in adults.[1]

Because the study is Phase 1/2 and has a small planned enrollment, it is mainly designed to gather early information rather than provide final proof of benefit.[1]

Trial ID Phase Condition studied Status Enrollment
2024-519790-19-00 Phase 1/2 Relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma Authorised 40

FAQ

  • What is being studied in HSP-CAR19M trials? The trials are studying HSP-CAR19M in adults with B-cell non-Hodgkin lymphoma. They look at safety, toxicity, and whether the treatment may help.
  • Who can take part in these trials? The trial data describe adults with relapsed or refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or follicular lymphoma. These are people whose disease has come back or has not responded well to treatment.
  • What phase is the HSP-CAR19M trial? The study is a Phase 1/2 trial. Phase 1/2 studies usually check safety first and then look at early signs of how well the treatment works.
  • What is the main goal of the trial? The main goal is to assess safety after infusion of HSP-CAR19M cells. In the expansion phase, the study also looks at efficacy, which means how well the treatment may work.
  • How many people are planned for the study? The trial plans to enroll 40 participants. This gives the researchers a small group to study safety and early treatment effects.

Ongoing Clinical Trials on HSP-CAR19M

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • B-cell non-Hodgkin lymphoma: A group of cancers that start in B cells, which are a type of white blood cell.
  • Relapsed: A disease that comes back after it had improved.
  • Refractory: A disease that does not respond well to treatment.
  • Large B-cell lymphoma: A fast-growing type of B-cell non-Hodgkin lymphoma.
  • Mantle cell lymphoma: A type of B-cell non-Hodgkin lymphoma that starts in the mantle zone of lymph nodes.
  • Follicular lymphoma: A type of B-cell non-Hodgkin lymphoma that often grows more slowly.
  • Phase 1/2: An early clinical trial phase that first checks safety and then looks at early signs of benefit.
  • Interventional study: A study where participants receive a treatment or procedure being tested.
  • Primary outcome: The main result the researchers want to measure.
  • Efficacy: How well a treatment works.
  • Infusion: A treatment given slowly into a vein.

References

  1. https://clinicaltrials.gov/study/2024-519790-19-00